New Oral Therapies for Psoriasis: A Comprehensive Review.
Conventional oral therapies for psoriasis, including methotrexate, cyclosporine, and acitretin, have generally unfavorable safety profiles and are not ideal for long-standing use. Thus, new oral therapies are necessary for patients with more moderate disease, patients who prefer oral treatments to injectable biologies, and patients who failed conventional therapies. The authors review here the clinical and safety evidence of phosphodiesterase 4 inhibitor, apremilast, janus kinase inhibitors, including tofacitinib, and fumarie acid esters as additional options in oral psoriasis therapy.
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
Gary
G
Goldenberg
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
Julien
J
Lanoue
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
Joanna
J
Dong
J Invest Dermatol. 2009 Sep;129(9):2299-302
19225543
J Am Acad Dermatol. 2010 Dec;63(6):925-46; quiz 947-8
21093659
J Am Acad Dermatol. 1988 Sep;19(3):458-68
2971692
Br J Dermatol. 2015 Dec;173(6):1387-99
26357944
Curr Med Res Opin. 2008 May;24(5):1529-38
18419879
Br J Dermatol. 2015 Sep;173(3):767-76
25704750
J Am Acad Dermatol. 2015 Jul;73(1):37-49
26089047
Lancet. 2012 Aug 25;380(9843):738-46
22748702
J Invest Dermatol. 2003 Dec;121(6):1383-8
14675187
Arthritis Res. 2002;4(4):266-73
12106498
Int J Dermatol. 2014 May;53(5):525-38
24601982
Br J Dermatol. 1999 Aug;141(2):283-91
10468801
Actas Dermosifiliogr. 2013 May;104(4):304-10
23583515
J Immunol Res. 2015;2015:906349
25973439
Br J Dermatol. 2012 Sep;167(3):668-77
22924949
Cochrane Database Syst Rev. 2015 Aug 10;(8):CD010497
26258748
Cell Immunol. 2009;258(2):115-22
19426966
J Immunol. 2000 Aug 15;165(4):2240-50
10925312
Drug Metab Dispos. 2014 Apr;42(4):759-73
24464803
Br J Pharmacol. 2010 Feb;159(4):842-55
20050849
Br J Dermatol. 2008 Mar;158(3):558-66
18047523
J Eur Acad Dermatol Venereol. 2012 Mar;26(3):361-7
21504485
Br J Dermatol. 2015 Oct;173(4):949-61
26149717
Lancet. 2015 Aug 8;386(9993):552-61
26051365